HepaFat-AI Receives TGA Approval

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to announce that it has received Australian Therapeutic Goods Administration (“TGA”) approval for HepaFat-AI, the Company’s fully automated artificial intelligence (“AI”) software that assesses liver fat (the “Device”).

Read more

HepaFat-AI gains US FDA clearance

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) announces that it has received 510(k) clearance from the US Food and Drug Administration (“FDA”) for HepaFat-AI, a medical device (software) that is fully automated and uses artificial intelligence (“AI”) to assess liver fat.

Read more

R&D Update: New Pulmonary Embolism AI Solution Developed

Further to the Company’s announcement on 17 October 2017 (‘Collaborative Partnership commences to develop new AI diagnostic tools’), Resonance Health Ltd is pleased to advise that it has developed a new artificial intelligence (AI) tool for the automated review of chest computed tomography (CT) scans of patients with suspected pulmonary embolism (PE).

Read more

Execution of Licence Agreement with Telethon Kids Institute and Erasmus University Medical Centre

Resonance Health Ltd is pleased to announce that it has entered into a licence agreement with the Telethon Kids Institute in Perth, Western Australia, and the Erasmus University Medical Centre, in Rotterdam, The Netherlands, for the use of computed tomography (“CT”) datasets that will be used by the Company in the potential development of a new artificial intelligence algorithm for the automated assessment of lung disease progression in patients with cystic fibrosis. 

Read more

Resonance Health Files New Provisional Patent

Resonance Health Limited is pleased to announce that it has filed a provisional patent covering the application of novel Antisense Oligonucleotides (ASOs) to treat liver related disease.

Read more

Resonance Health News - April 2020

Resonance Health is delighted to provide you with our latest customer newsletter, where you can find an update on all our latest acitvities.

To read the newsletter please click here